On a Mediterranean island once plagued by mosquitoes, a quiet genetic twist in human blood cells is rewriting the malaria playbook.
Researchers in Italy say a rare gene variant, shaped by centuries of disease on Sardinia, appears to blunt the malaria parasite from inside red blood cells, offering a fresh route to treatments at a time when drug resistance is on the rise.
A tiny island clue to a massive global problem
Malaria still infects more than 200 million people every year and kills over 600,000, the vast majority of them in sub-Saharan Africa. Despite bed nets, insecticides and modern drugs, the parasite Plasmodium falciparum continues to adapt and slip past many defences.
In this long battle, human DNA has not stayed neutral. In different regions, repeated waves of infection have left genetic marks: some mutations make red blood cells less welcoming to the parasite, even at the cost of other health problems.
Now, a team led by geneticist Francesco Cucca at the University of Sassari and Italy’s National Research Council has highlighted a new piece of this evolutionary arms race: a rare variant in a gene called CCND3, common in Sardinia but scarce almost everywhere else, that seems to reduce the parasite’s ability to multiply.
This Sardainian gene variant subtly remodels red blood cells so that malaria parasites can still get in, but struggle to survive.
The study, published in Nature, draws on genetic and blood data from thousands of island volunteers and suggests a mechanism that drug developers could realistically imitate without rewriting anyone’s DNA.
How an isolated island became a natural laboratory
Sardinia, better known today for beaches and summer tourism, was for centuries one of Europe’s malaria hotspots. The disease was formally wiped out from the island only in the 1950s, after extensive public-health campaigns.
Before eradication, repeated infection cycles placed powerful selective pressure on local communities. People carrying even slightly protective mutations would have had a better chance of reaching adulthood and having children. Over hundreds or thousands of years, those variants could slowly spread.
Using the SardiNIA project as a genetic magnifying glass
The new work relies on the SardiNIA project, a long-running study that has followed thousands of Sardinians with detailed genetic and medical records. The research team analysed the genomes of around 7,000 participants and compared them with a wide panel of blood measurements.
➡️ In Japan, a toilet paper revolution no one saw coming
➡️ Mark Zuckerberg’s AI announcement shakes the global scientific community
➡️ Most smartphones collect this data by default, but turning it off takes seconds
One signal stood out: a specific alteration in the CCND3 gene, known as rs112233623-T, showed a strong association with unusual red blood cell traits.
- The variant appears in roughly 10% of the Sardinians studied.
- Its frequency is far lower in other European populations.
- Genomic signatures point to “positive selection”, meaning the variant likely provided a reproductive advantage in the past.
That pattern, combined with Sardinia’s well-documented malaria history, strongly suggests the island’s parasite burden helped boost the spread of this rare gene version.
The CCND3 variant is not a random quirk of island genetics; it bears the fingerprints of natural selection under heavy malaria pressure.
What CCND3 actually does to red blood cells
CCND3 encodes cyclin D3, a protein that helps control how precursor cells in the bone marrow divide as they mature into red blood cells. By acting as a kind of timing regulator for cell division, cyclin D3 influences both the size and number of red blood cells released into circulation.
In people carrying the Sardinian variant, CCND3 activity is dialled down. The researchers found that red blood cell precursors divide fewer times before maturing. That leads to red blood cells that are slightly larger and produced in altered quantities, yet still compatible with overall good health.
A hostile home for the malaria parasite
The crucial twist appears once Plasmodium falciparum moves into these modified cells. In lab tests, red blood cells from people with the variant showed higher levels of oxidative stress. Inside, there were more “reactive oxygen species”, chemically active molecules often linked to cellular damage.
For the malaria parasite, that changed chemistry is bad news. P. falciparum relies on a delicately balanced environment inside red blood cells. It feeds on haemoglobin and hijacks the cell’s machinery to copy itself. Extra oxidative stress disrupts these processes and slows parasite growth.
The parasite can still infect these red blood cells, but its replication rate drops as the internal chemistry turns slightly more toxic.
The protection is not absolute in the way a vaccine might be, yet even a modest reduction in parasite multiplication can translate to milder infections and better odds of survival at the population level.
Fitting into the bigger story of genetic resistance
The Sardinian CCND3 variant sits alongside better-known protective mutations such as sickle cell trait and G6PD deficiency. All are shaped by the same evolutionary force: intense and repeated exposure to malaria.
Sickle cell trait alters the shape and flexibility of red blood cells, hampering the parasite but increasing risks of severe disease when inherited from both parents. G6PD deficiency raises vulnerability of red cells to oxidative damage, which again makes life harder for P. falciparum, yet brings its own complications, like sensitivity to certain drugs and foods.
The CCND3 variant seems to tap into a similar redox theme, with enhanced oxidative stress inside red blood cells. But it arrives at that state differently, through a shift in how the cells are produced rather than a direct enzyme defect.
This distinction matters for drug design. Modestly changing the behaviour of a cell cycle gene in red blood cell precursors could, in theory, be mimicked with medicines for a limited period of time, in a controlled way, during high-risk seasons or acute infection.
A new angle for malaria treatment strategies
Most current antimalarial drugs attack the parasite directly. Over time, the parasite often evolves resistance, forcing continual updates and combinations of medicines. Vaccines, while promising, have so far offered only partial and sometimes short-lived protection.
The Sardinian gene finding supports a different strategy: target the host environment instead of the parasite alone.
| Traditional approach | Host-based approach inspired by CCND3 variant |
|---|---|
| Kill or disable the parasite with drugs that act on its proteins. | Make red blood cells less hospitable so the parasite multiplies less efficiently. |
| High risk of resistance as the parasite mutates. | Lower resistance risk, since the target is human biology, which changes more slowly. |
| Can be very effective but often needs new compounds. | Could complement existing drugs and vaccines rather than replace them. |
Cucca and colleagues argue that if nature has already stress-tested a partial reduction in CCND3 activity in humans, and those people remain broadly healthy, then pharmacologists can look for ways to reproduce that effect temporarily.
Instead of editing genes, future therapies might gently nudge the same pathways that evolution has already trialled in Sardinian families.
Any such treatment would need careful calibration. Cyclin D3 participates in cell division, a core process across the body. Interfering too strongly could damage blood production or affect other tissues. Researchers now want to map the precise molecular chain that links lower CCND3 expression to extra oxidative stress in red cells, and then look for safe intervention points.
What this means beyond Sardinia
Though the CCND3 variant itself is rare outside Sardinia, the underlying biology is universal. Every human relies on the same basic machinery to make red blood cells. Therapies inspired by this island-specific adaptation could, at least in principle, help children in Nigeria or pregnant women in India just as much as people in the Mediterranean.
The study also underscores why genetic surveys in historically neglected regions and small populations matter. Protective variants against malaria have been found in Africa, Asia and the Pacific, and now in greater detail in a European island community. Each one points to a slightly different vulnerability in the parasite’s lifecycle.
Key terms and concepts worth unpacking
For readers less familiar with the jargon, two notions sit at the heart of this story: oxidative stress and natural selection.
Oxidative stress refers to an imbalance between reactive oxygen species (ROS) and the body’s ability to neutralise them. ROS can damage DNA, proteins and cell membranes, yet at controlled levels they also serve as useful signals and weapons against microbes. In the Sardinian variant, red blood cells operate with a mild, chronic increase in oxidative molecules. That seems enough to unsettle the parasite without causing obvious disease in the host.
Natural selection describes how traits that slightly increase survival or reproduction become more common over generations. With malaria, even a small reduction in the risk of fatal infection in childhood can drastically increase the likelihood of having offspring. That is why genes with modest protective effects, like the CCND3 variant, can become enriched in certain populations over time.
What future treatments inspired by this research might look like
Scientists are already sketching out what CCND3-based strategies could involve. Concrete possibilities include:
- Short-course drugs that temporarily reduce CCND3 activity in bone marrow, leading to a wave of red blood cells less suitable for parasite growth during peak transmission seasons.
- Compounds that fine-tune oxidative stress in red cells, raising it just enough to slow P. falciparum without triggering severe damage or anaemia.
- Combination therapies, pairing conventional antimalarials with host-directed agents, to cut both parasite numbers and the chances of resistance emerging.
Each of these ideas faces challenges: measuring the right dose, avoiding harm to other tissues, dealing with variations between patients. Yet the guiding principle is clear: by reading the lessons written in the genomes of Sardinian villagers, researchers gain a roadmap for a new generation of malaria interventions that lean on human biology as much as on chemical attack.